Skip to main content
Tanawin Nopsopon on Muck Rack

Tanawin Nopsopon

As seen in: Wiley Online Library, ScienceDirect, BMJ Open, Frontiers, MDPI, JAMA Oncology, Respiratory Research, EClinicalMedicine, The Lancet, Dove Medical Press and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tanawin

Contact Tanawin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of clinical factors and season on inflammatory cytokines in biologic-treated and untreated asthma - Respiratory Research

|
By Tanawin Nopsopon, Javier Cabrera-Perez, Pui Lee, Kailey E. Brodeur, Njira L. Lugogo, Georg Hahn, Steven Carr, Scott Weiss, Ayobami T. Akenroye, Evan E. Hsu, Courtney LeSon
| Respiratory Research Verified
Of 238 patients with moderate-to-severe asthma, 162 were not receiving biologic therapy but met criteria for a biologic and 76 were on omalizumab, mepolizumab, benralizumab, or dupilumab. Both groups had similar mean age, female proportion, and BMI (Table 1). Patients not on biologic therapy at the time of sample collection were like those on biologic therapy on clinical and demographic characteristics. However, they had a lower exacerbation burden in the year prior to sample collection (1.2 vs.
Open in Who Shared Issue with article?

Patients with higher exacerbation burden and eosinophil counts are mor

|
By Alyson Brown, Tanawin Nopsopon, Ayobami T. Akenroye
| Dove Medical Press
Introduction With six biologic therapies currently approved for the treatment of moderate-to-severe asthma, there are ample opportunities for patients to switch between biologics to achieve asthma control.1,2 While suboptimal response is the leading reason for switching respiratory biologics,3–5 little is known about the characteristics of patients who switch. Identifying these features could help anticipate poor responders.
Open in Who Shared Issue with article?

Cannabis and cannabinoids in dermatology: a systematic review and meta-analysis of quantitative outcomes

|
By Pim Sermsaksasithorn, Tanawin Nopsopon, Chatpol Samuthpongtorn, Korn Chotirosniramit, Krit Pongpirul
| Frontiers
1Center of Excellence in Preventive and Integrative Medicine and Department of Preventive and Social Medicine, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand 2School of Global Health, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand 3Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States 4Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,...
Open in Who Shared Issue with article?
See all 19 articles